Patients with high FABP7 expression in breast cancer have poor responses to neoadjuvant chemotherapy (e.g., paclitaxel and anthracyclines), but its expression level can predict the efficacy of anti-angiogenic drugs (e.g., apatinib)[143]. The gene discussed is FABP7; the disease is breast carcinoma.